Johnson & Johnson (Johnson & Johnson) Change in Organic Revenue % : 7.20% (As of Dec. 2023)

View and export this data going back to 1944. Start your Free Trial

What is Johnson & Johnson Change in Organic Revenue %?

Organic revenue is revenue generated from within a company that is a direct result of the firm's existing operations. Change in Organic Revenue % provides management and investors with the level of revenue change that was generated from the sale of a company's products and services.

Johnson & Johnson's Change in Organic Revenue % for the quarter that ended in Dec. 2023 was 7.20% , which is higher than 6.40% for the pervious quarter ended in Sep. 2023.

Johnson & Johnson's Change in Organic Revenue % for the annual that ended in Dec. 2023 was 7.40% , which is higher than 6.10% for the pervious year ended in Dec. 2022.

The historical rank and industry rank for Johnson & Johnson's Change in Organic Revenue % or its related term are showing as below:

JNJ's Change in Organic Revenue % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median:
* Ranked among companies with meaningful Change in Organic Revenue % only.

Johnson & Johnson Change in Organic Revenue % Historical Data

The historical data trend for Johnson & Johnson's Change in Organic Revenue % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Change in Organic Revenue % Chart

Johnson & Johnson Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change in Organic Revenue %

Get a 7-Day Free Trial

Johnson & JohnsonQuarterly Data

Trend

Mar19

Jun19

Sep19

Dec19

Mar20

Jun20

Sep20

Dec20

Mar21

Jun21

Sep21

Dec21

Mar22

Jun22

Sep22

Dec22

Mar23

Jun23

Sep23

Dec23

Change in Organic Revenue %

Get a 7-Day Free Trial

Competitive Comparison of Johnson & Johnson's Change in Organic Revenue %

For the Drug Manufacturers - General subindustry, Johnson & Johnson's Change in Organic Revenue %, along with its competitors' market caps and Change in Organic Revenue % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Johnson & Johnson (NYSE:JNJ) Change in Organic Revenue % Explanation

Organic revenue is the product of the internal processes of a company and are generated solely within the firm minus cost of goods sold (COGS). It’s similar to the gross income. Organic revenue provides management and investors with the level of revenue that was generated from the sale of a company's products and services.

If the change in organic revenue is positive, then the company generates increases in organic revenue, which is typically referred to as organic growth. Once an acquisition is fully integrated into a company's existing operations, sales from the acquired unit or business would then be counted as organic sales.

Organic revenue is important because it doesn't include taxes and other one-off items that may skew a company's profit in a given year. The changing of the organic revenue also reflects the company’s core business profitability is increasing, especially when an acquisition happened. It is a more reliable index than gross income at that time because the performance of newly acquired businesses may change in the future.

Johnson & Johnson (Johnson & Johnson) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (NYSE:JNJ) » Definitions » Change in Organic Revenue %

Comparable Companies

Traded in Other Exchanges

JNJ:Peru JNJ:Mexico JNJ_KZ:Kazakhstan 1JNJ:Italy JNJd:UK 0R34:UK JNJ0:Germany JNJ:Germany JNJ:Germany JNJ:Germany JNJ:Germany JNJ:Canada JNJB34:Brazil JNJ:Austria JNJ:Argentina

Address

One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933

Website

https://www.jnj.com

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.

Executives

Timothy Schmid	officer: EVP, WW Chair, MedTech	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
William Hait	officer: See Remarks	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Peter Fasolo	officer: VP, Worldwide Human Resources	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Kathryn E Wengel	officer: EVP, Chief GSC Officer	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
John C Reed	officer: EVP, Pharmaceuticals R&D	ONE JOHNSON & JOHNSON PLAZA, WHQ 2134, NEW BRUNSWICK NJ 08933
James D. Swanson	officer: EVP, Chief Information Officer	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Paula A Johnson	director	22 CHERRY HILL DRIVE, DANVERS MA 01923
Joseph J Wolk	officer: Exec VP, CFO	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Ashley Mcevoy	officer: EVP, WW Chair, Medical Devices	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Jennifer L Taubert	officer: EVP, WW Chair, Pharmaceuticals	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Robert J Decker	officer: Controller, CAO	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Thibaut Mongon	officer: Exec VP, WW Chair, Consumer	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Elizabeth Forminard	officer: Executive VP, General Counsel	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Darius Adamczyk	director	855 S. MINT STREET, CHARLOTTE NC 28202
Vanessa Broadhurst	officer: EVP, Global Corp Aff.	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933